Souhaitez-vous accéder aux communiqués récents ?

Konzernverkäufe stiegen um 2%1 zu konstanten Wechselkursen (CER; -6% in CHF) dank starkem Wachstum der jüngeren Medikamente und Diagnostika; ohne COVID-19-Produkte nahmen die Konzernverkäufe um 7% zu;...

Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung...

Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%)...

Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphoma Data from the...

The Elecsys® pTau217 plasma biomarker test is being developed as part of an ongoing partnership between Roche and Eli Lilly and CompanyOnce approved, the test will aid healthcare providers in...

The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malariaMalaria is a serious and potentially fatal parasitic infection most commonly transmitted by...

Alle Anträge des Verwaltungsrates genehmigtSeverin Schwan erneut als Präsident des Verwaltungsrates gewählt; alle weiteren zur Wahl stehenden Verwaltungsrätinnen und Verwaltungsräte bestätigt 37....

All proposals of the Board of Directors approvedSeverin Schwan re-elected as Chairman of the Board of Directors; all other Board members standing for election confirmed37th consecutive dividend...

Adoption de toutes les propositions du Conseil d’administrationRéélection de Severin Schwan à la présidence du Conseil d’administration ; confirmation de tous les autres membres du Conseil...

KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure reductions in each treatment arm at month three Zilebesiran added to a standard of care...